Your browser doesn't support javascript.
loading
Cross-sectional burden-of-illness study in atopic dermatitis (MEASURE-AD) in Australia and New Zealand reveals impacts on well-being.
Rademaker, Marius; Jarrett, Paul; Murrell, Dedee F; Sinclair, Rodney D; Pasfield, Lauren; Poppelwell, David; Shumack, Stephen.
Afiliación
  • Rademaker M; Clinical Trials New Zealand, Hamilton, New Zealand.
  • Jarrett P; Department of Dermatology, Middlemore Hospital, Counties Manukau Health, The University of Auckland, Auckland, New Zealand.
  • Murrell DF; Department of Medicine, The University of Auckland, Auckland, New Zealand.
  • Sinclair RD; Department of Dermatology, St George Hospital, Sydney, New South Wales, Australia.
  • Pasfield L; University of Melbourne and Sinclair Dermatology, Melbourne, Victoria, Australia.
  • Poppelwell D; AbbVie Pty Ltd, Sydney, New South Wales, Australia.
  • Shumack S; AbbVie Limited, Auckland, New Zealand.
Australas J Dermatol ; 2024 May 21.
Article en En | MEDLINE | ID: mdl-38773888
ABSTRACT

OBJECTIVES:

To describe disease burden in individuals with moderate-to-severe atopic dermatitis (AD) in Australia and New Zealand (ANZ) and compare it with other geographic regions.

METHODS:

This multicentre, cross-sectional, observational study (MEASURE-AD) recruited consecutive adolescent and adult patients attending dermatology clinics in 28 countries. Data collected included scores of pruritus, disease severity, sleep, pain, disease control, work and quality of life.

RESULTS:

This study included 112 ANZ participants (Australia n = 72; New Zealand n = 40) from December 2019 to December 2020. Treatments included topicals (85.7% of patients), non-biologic systemic therapy (28.6%), phototherapy (9.8%) and dupilumab (4.5%). Mean Eczema Area and Severity Index (EASI) score was 22.3 (95% CI 19.6-25.0) and Patient-Oriented Eczema Measurement (POEM) score was 18.4 (95% CI 16.8-20.0). Pruritus Numerical Rating Scale (NRS) was 6.0 (95% CI 5.5-6.6) (50% had severe pruritus) and Dermatology Life Quality Index (DLQI) 14.3 (95% CI 12.8-15.8). ADerm-Impact sleep domain score was 15.1 (95% CI 13.2-16.9). ADerm-Symptom Scale worst skin pain domain score was 5.0 (95% CI 4.3-5.6). Work Productivity and Activity Impairment (WPAI) percentages indicated work and productivity impairment. Inadequately controlled AD was self-reported by 41%, with 9.7 flares in the past 6 months. Scores of pruritus, disease severity, sleep, pain, disease control and quality of life in ANZ were often the highest of all the geographic regions studied.

CONCLUSION:

ANZ patients with AD have a high disease burden, which extends across multiple facets of daily life. Many are inadequately controlled with existing therapies.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Australas J Dermatol Año: 2024 Tipo del documento: Article País de afiliación: Nueva Zelanda Pais de publicación: Australia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Australas J Dermatol Año: 2024 Tipo del documento: Article País de afiliación: Nueva Zelanda Pais de publicación: Australia